Penumbra Free Cash Flow 2014-2024 | PEN

Penumbra free cash flow for the twelve months ending June 30, 2024 was , a year-over-year.

  • Penumbra annual free cash flow for 2023 was $0.081B, a 208.24% decline from 2022.
  • Penumbra annual free cash flow for 2022 was $-0.075B, a 541.88% increase from 2021.
  • Penumbra annual free cash flow for 2021 was $-0.012B, a 64.87% decline from 2020.

Penumbra Free Cash Flow 2014-2024 | PEN

  • Penumbra annual free cash flow for 2023 was $0.081B, a 208.24% decline from 2022.
  • Penumbra annual free cash flow for 2022 was $-0.075B, a 541.88% increase from 2021.
  • Penumbra annual free cash flow for 2021 was $-0.012B, a 64.87% decline from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$236.9B
Intuitive Surgical (ISRG)$174.1B
Alcon (ALC)$48.5B
IQVIA Holdings (IQV)$44.6B
IDEXX Laboratories (IDXX)$42.6B
Edwards Lifesciences (EW)$40.5B
DexCom (DXCM)$28.8B
STERIS (STE)$23.6B
SONOVA HOLDING (SONVY)$21B
Waters (WAT)$20.1B
Hologic (HOLX)$19.1B
Sysmex ADR (SSMXY)$12.5B
Fresenius Medical Care AG KGaA (FMS)$12.2B
Teleflex (TFX)$11.6B
Globus Medical (GMED)$9.6B
Glaukos (GKOS)$7.1B
Masimo (MASI)$5.9B
TransMedics (TMDX)$5.5B
Integer Holdings (ITGR)$4.4B
PROCEPT BioRobotics (PRCT)$4.3B
Tandem Diabetes Care (TNDM)$2.9B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.7B
Inari Medical (NARI)$2.6B
Elekta AB (EKTAY)$2.5B
Nihon Kohden (NHNKY)$2.3B
RxSight (RXST)$2B
Integra LifeSciences Holdings (IART)$1.4B
Pulse Biosciences (PLSE)$1.1B
AVANOS MEDICAL, INC (AVNS)$1.1B